1

Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: A matched case-control study

Espoir Bwenge Malambaka[1,2], Patrick Musole Bugeme[1,2], Chloe Hutchins[3], Hanmeng Xu[1], Juan Dent Hulse[1], Maya N. Demby[1], Karin Gallandat[3], Jaime Mufitini Saidi[4], Baron Bashige Rumedeka[1,4], Moïse Itongwa[1], Esperance Tshiwedi-Tsilabia[5], Faida Kitoga[5], Tavia Bodisa-Matamu[5], Hugo Kavunga-Membo[5,6], Justin Bengehya[7], Jean-Claude Kulondwa[7], Amanda K Debes[8], Nagède Taty[9], Elizabeth C. Lee[1], Octavie Lunguya[6,10], Justin Lessler[1,11,12], Daniel T Leung[13,14], Oliver Cumming[3], Placide Welo Okitayemba[9], Daniel Mukadi-Bamuleka[5,6,10], Jackie Knee[3], Andrew S Azman[1,15,16*]

[1]*Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA*

[2]*Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo*

[3]*Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK*

[4]*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo*

[5]*Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the Congo*

[6]*Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo*

[7]*Ministère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Santé Publique du Sud-Kivu, Democratic Republic of the Congo*

[8]*Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA*

[9]*PNECHOL-MD, Community IMCI, Ministry of Health, Democratic Republic of the Congo*

[10]*Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo*

[11]*University of North Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

[12]*Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

[13]*Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah, USA*

[14]*Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA*

15Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,
Switzerland

16Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva,
Switzerland

* Correspondence to:

Dr Andrew S Azman,
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
Johns Hopkins University, Baltimore, MD 21205, USA
azman@jhu.edu

Abstract

Background

A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is limited evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-plus in this high-burden setting.

Methods

We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-matched community controls during two distinct periods after mass vaccination, October 2021 to March 2022 (12-17 months post-vaccination) and October 2022 to May 2023 (24-31 months post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.

Findings

We enrolled 434 confirmed cases and 1562 matched controls during the two study periods with 21.7% of cases being under five years old at the time of vaccination. The adjusted single-dose VE was 52% (95% CI: 32·3–66) 12-17 months post-vaccination and 40·8% (95% CI: 8·6–61·7) 24-31 months post-vaccination. While protection in the first 17 months post-vaccination among those under five years old was similar to older individuals, after two years under-five-year-olds appeared to be less protected (adjusted VE 31.9%; 95% CI: -58.5–70.8) though with large uncertainty.

Interpretation

A single-dose of Euvichol-Plus provided substantial protection against medically attended cholera for at least 31 months post-vaccination in this cholera endemic setting though our limited sample size in under-five-year-olds limited our ability to make strong conclusions about protection in this age group.

Funding

Wellcome Trust and Gavi (GAVI-RFP-2019-062).

Introduction

Safe water, sanitation, and hygiene (WASH) is the cornerstone of cholera prevention and control. While universal access to safely-managed WASH services remains the ultimate priority, this is likely a distant prospect.[1] Killed whole-cell oral cholera vaccine (kOCV) is an effective short-term intervention to reduce cholera risk in high-burden settings with limited WASH coverage and is a key component of the global roadmap to end cholera.[2] kOCVs are typically delivered as a two-dose regimen that provides protection for at least three years.[3,4] In a meta-analysis of kOCV protection, estimated two-dose efficacy was 58% (95% CI: 42 to 69), over an average of 28 months post-vaccination. Lower protection was noted among young children.[3]

The Euvichol-Plus® vaccine (Eubiologics, Seoul, Republic of Korea) is currently the only WHO-prequalified kOCV manufactured and included in the global stockpile after the Shanchol® (Shantha Biotechnics, Hyderabad, India) ceased production in 2023.[5] Euvichol-Plus® is considered a bioequivalent of Shanchol®.[6] Almost all evidence of kOCVs clinical protection is based on the studies carried out on Shanchol®,[7–9] although one observational study explored the protection conferred by a Euvichol-Plus® two-dose regimen.[10]

Demand for kOCVs outstripped the global supply in 2022, with only 23·5 million doses distributed out of the 33 million requested.[11] In late 2022, the International Coordinating Group, which manages the global emergency stockpile for cholera vaccines, suspended the provision of the standard two-dose regimen in emergency vaccination campaigns, replacing it with a single-dose regimen due to limited vaccine supply.[12] However, there are limited data on the protection offered by one dose of kOCV over extended periods (>12 months) or among children 1-4 years old.

Only a few studies have estimated single-dose protection in the general population, with point estimates suggesting short-term protection up to 16 months after vaccination in Haiti, though with large uncertainty. [7–9,13–16] A randomized trial in Bangladesh, the only study to provide age-stratified estimates of single-dose protection, suggested that Shanchol® conferred no protection in 1-4 year olds in the first six months post-vaccination, despite significant protection in older individuals for at least two years.[17,18]

In late 2020, the Ministry of Health of the Democratic Republic of the Congo (DRC) conducted a mass vaccination campaign of Euvichol-Plus® in the city of Uvira in theSouth Kivu province. The estimated coverage of the vaccination campaigns was low, and as most vaccinated individuals reported receiving one dose only, we assessed effectiveness of a single dose of kOCV during outbreaks that occurred 12-17 and 24-31 months after vaccination.

Study design, setting and vaccination campaigns

We conducted a matched case-control study in Uvira, a city of approximately 280,000 inhabitants on the northwestern shore of Lake Tanganyika with sporadic armed conflict, socio-

political instability and population displacement. Cholera cases are detected year-round in Uvira
since 1978, often with distinct seasonal peaks and notable historical outbreaks.[19,20] Household
surveys conducted in 2016/17 in Uvira indicated surface water as the main drinking water source
for 37.2% of households,[21] and in areas close to the rivers and with the lowest tap water
availability, >80% of households use drinking water contaminated with *Escherichia coli.*[22] The
same surveys estimated that about half (48.2%) of the population relied exclusively on tap water
for drinking needs [21], and a recent study showed that between 2017 and 2021, the water service
quality remained suboptimal, or deteriorated in many parts of the city.[23] [20]

In April 2020, severe flooding caused at least 54 deaths, the displacement of approximately
80,000 people, and substantial damage to housing and WASH infrastructure in Uvira, prompting
the Ministry of Health to conduct emergency cholera vaccination campaigns.[24] Vaccination took
place in two rounds, from 29 July to 8 August and 1-8 October 2020 targeting all individuals in
Uvira one year and older. The campaigns included door-to-door vaccination for five days,
followed by vaccination offered through health facilities. While two rounds of vaccination were
implemented, in a representative household survey we conducted 11 months after vaccination,
23.1% (95% CI: 20-27%) of the participants reported receiving two doses of the vaccine and
32% (95% CI: 38-36%) reported receiving one dose. No kOCV has been administered in this
population between these campaigns and the end of our study period, May 2023.

Clinical cholera surveillance system in Uvira

Our study is based on enhanced clinical surveillance of cholera implemented at the two official
health facilities designated to treat cholera patients in Uvira, the cholera treatment centre at the
Uvira General Referral Hospital and the cholera treatment unit at the Kalundu CEPAC health
centre (henceforth, "CTCs"). We attempted to identify and recruit all patients at least 12 months
old with acute watery diarrhoea within the 24 hours prior to the admission to the CTCs (referred
to as 'suspected cholera'). Trained healthcare staff collected rectal swabs and stools from
participants. Rectal swabs were enriched in alkaline peptone water (APW) for 6-18 hours
depending on patient admission time. Specimens were tested for *V. cholerae* by rapid diagnostic
tests (RDTs) onsite, and by culture using standard methods (Appendix) at either an in-country
reference laboratory, the Laboratoire Rodolphe Mérieux de l'Institut National de Recherche
Biomédicale (INRB), in Goma (from October 2021 to September 2022), or at the onsite study
laboratory (from September 2022 onward). As PCR for *V. cholerae* O1 was not available at
either study laboratory in DRC, we shipped stool specimens (stool spotted on dry filter papers)
for cases enrolled between October 14, 2021 and May 04, 2022 to Johns Hopkins University for
PCR detection of toxigenic *V. cholerae* O1 following published methods.[25]

Selection of cases and controls

Two cholera outbreaks occurred after mass vaccination, and we recruited cases during each
outbreak, forming two distinct study periods (Figure 1). From 21 November 2022 to 24 January

2023, we retrospectively recruited controls for patients admitted to CTCs during the first
outbreak (14 October 2021 to 10 March 2022), approximately 12-17 months after the second
round of mass vaccination campaigns (Study Period 1). Between 17 October 2022 and 9 May
2023, we recruited controls for cases as they were admitted to the CTCs, 24-31 months after
vaccination (Study Period 2).

Study Period 1 (SP1) included all consenting suspected cases who were at least 12 months old
during the vaccination campaigns, living in Uvira for the two weeks prior to admission to the
CTC and during the 2020 vaccination campaigns, and who tested positive for cholera by culture
and/or PCR. We attempted to recruit four controls per case, using high-resolution satellite
imagery (Appendix) to identify potential control households on the same avenue (smallest
administrative unit in Uvira) as the case household. Control households were then selected by
simple random spatial sampling of digitized residential structures. Controls were eligible for
enrollment if: (1) they matched the case age group (1-4, 5-9, 10-19, 20-39, 40-59 or ≥60 years
old) and sex, (2) had not been admitted for acute watery diarrhoea or cholera in the three years
prior to the case admission, (3) were living in Uvira in the two weeks prior to case admission, (4)
were living in Uvira at the time of the 2020 kOCV campaign and were eligible to be vaccinated,
and (5) none of their household members reported being admitted to a formal health facility (as
opposed to pharmacies, prayer homes or traditional healers) for acute watery diarrhoea or cholera
in the four weeks prior to case admission.

During Study Period 2 (SP2), the case definition included the same age and residence criteria as
in SP1, but cases had to test positive with both APW-enriched rapid diagnostic test (RDT) and
culture (performed at the onsite laboratory). We used enriched RDT results to help prioritize
control recruitment due to limited human resources during the outbreak. In contrast to SP1, we
conducted a home visit within three days of hospital discharge to investigate the living and
WASH conditions in each case's household and ascertain the vaccination status outside the
hospital environment (as done with the controls). We excluded patients who died during
hospitalization and those whose residence could not be found during home visits. As in SP1, four
neighborhood controls were recruited from four randomly selected households near the case
household, though during this study period we selected households using the 'right-hand' rule
(Appendix). In addition to the recruitment criteria used in SP1, controls were eligible for
enrolment in SP2 if their household matched that of the case by size (≤5 individuals, 6-10
individuals, and >10 individuals) and had at least one child below five years of age when the
case household had one.

Vaccination status ascertainment and potential confounding variables

Study staff administered structured questionnaires to all cases and controls (or their
parent/guardian) to capture demographics, household conditions, potential confounding variables
and vaccination status. Before asking each case or control whether they were vaccinated, study
staff showed them photos of the vaccine vials and of someone taking the vaccine in addition to

explaining when and how the vaccines were delivered in Uvira, and how these may differ from
other campaigns and routine vaccines. Participants reporting vaccination were asked the number
of doses and when and where each one was taken. We also used vaccination cards to verify the
vaccination status whenever possible. In SP1, vaccine-related questions were asked to cases in
the clinic and in SP2 they were asked both in the clinic and a subsequent home visit. Any
differences in the vaccination status reporting between the clinic and household interviews were
solved through a third interview at the case's household followed by a review of the data,
discussion, and consensus within the study team. We identified potential confounders based on a
causal directed acyclic graph developed before the start of the study and attempted to measure
these through the interviews.

Statistical analyses

The characteristics of case and control participants were compared using the standardized mean
difference (SMD), which is the absolute difference in mean values of a variable between cases
and controls divided by the pooled standard deviation. In addition, we calculated p-values from
univariate conditional logistic regression models with case-control status as the dependent
variable. In the primary analysis, we compared the odds of being vaccinated with a single kOCV
dose between cases and controls using conditional logistic regression models. Those reporting to
have received 2 or more doses were dropped from the primary analyses. The vaccine
effectiveness (VE) was calculated as one minus the estimated odds ratio of having received a
single dose of vaccine, between cases and controls. To produce consistent age-group specific and
overall estimates of effectiveness across all ages, the conditional logistic regression model
included an interaction term for age group (1-4 vs. ≥5) and the vaccination status. We derived the
overall VE estimate based on a linear combination of parameters from the two age groups,
weighted by the proportion of cases within each, and estimated simultaneous confidence
intervals with the ghlt function in the multcomp R package.[26] For combined estimates (SP1/2)
and those from SP1, we incorporated age as a continuous variable (separately by the two age
groups) to adjust for potential confounding. For SP2, estimates were adjusted for a set of
potential confounders including age and household size (second degree polynomial), household
wealth index (as a continuous variable) derived from a principal component analysis of
household assets ownership (Appendix), type of sanitation facility, whether the participant used a
toilet shared by multiple households compared to using a private toilet, drinking water sources,
and availability of a hand washing facility and soap. For continuous variables, we explored
models using polynomials and restricted cubic splines, and compared them using Akaike
Information Criterion (AIC). We also fit three alternative models with different sets of covariates
to assess the robustness of the estimates (Appendix). In a secondary analysis, we estimated the
VE for at least one dose and two doses of kOCV compared to the unvaccinated group. While we
primarily relied on point estimates and 95% confidence intervals (CI) to assess the weight of
evidence, we considered p-values statistically significant when they were less than 0.05.
Analyses were performed in R (version 4.2.3).

Ethical considerations

Ethical approvals were obtained from Institutional Review Boards of the Johns Hopkins
Bloomberg School of Public Health (IRB00015785), the London School of Hygiene & Tropical
Medicine (25365) and the École de Santé Publique at the University of Kinshasa
(ESP/CE/65/2021). Written informed consent was obtained from all participants ≥18 years, with
written assent from those <18 years in addition to written consent from their parent/guardian.

Role of the funding source

The funders of the study had no role in study design, data analysis, interpretation, preparation of
this manuscript, or the decision to publish.

Results

Cholera incidence in Uvira and recruitment of study participants

We recruited 434 unique confirmed cholera cases and 1562 matched controls during the two
study periods (Figure 1), with 38·5% of cases enrolled in the second period. The median age of
participants at the time of the vaccination campaigns was 14·0 (interquartile range 5·0, 30·0)
years and 22·4% were under five years old (Table 1). Fifty six percent of cases were recorded as
severely dehydrated on admission. Cases were significantly older during the first study period
compared to the second period (p<0.001) though they all had similar dehydration status (Table
S2). Of the 309 culture positive isolates, 275 (89·0%) were serotype Ogawa, the rest were Inaba,
including 4·8% (n=8/167) Inaba in SP1 and 18·3% (n = 26/142) Inaba in SP2.

Figure 1. Number of cholera cases admitted to cholera treatment facilities in Uvira. Panels
A (Study Period 1) and B (Study Period 2) illustrate the cumulative number of confirmed cases
in each study period by neighborhood (avenue) across the city, with the locations of the two
health facilities where patients were recruited shown as dots. There were 14 cases living in
neighboring communities outside the city boundaries that were included in Study Period 2. The
second outbreak (Study Period 2) started in the northern part of the city and spread to a refugee
camp where many residents were admitted to the CTC but not included in the study as they were
not living in Uvira at the time of vaccination. Panel C illustrates the epidemic curve of suspected
and confirmed cholera cases admitted to the cholera treatment center (CTC) at the Uvira General
Referral Hospital and the cholera treatment unit (CTU) at the Kalundu CEPAC health center.
Cholera was confirmed by culture or PCR (Study Period 1), or by APW-enriched RDT and
culture (Study Period 2). Among the 183 suspected cases that were detected before SP1 (in
grey), 146 (79·8) were tested for *Vibrio cholerae* O1 by enriched RDT with 37 (25·3%) testing
positive.

Overall, 22·1% of cases reported receiving one dose of kOCV and 65·7% were unvaccinated. In
comparison, 33·7% of matched controls reported receiving a single dose of kOCV and 53·3%
were unvaccinated. Only 13·6% of vaccinated participants were able to show a vaccination card
and 12·8% reported having received two doses of the vaccine (Table 1).

297
298 **Figure 2**. Flow chart of participant recruitment. Cases with unavailable culture results are those
299 for which 1) suspected colonies were isolated, 2) with positive oxidase test at the field
300 laboratory, 3) missing agglutination results due to an antiserum stockout, 4) and/or in which
301 attempts to revitalize *Vibrio cholerae* O1 strains at the reference laboratory in Goma were
302 unsuccessful.
303

304 **Table 1: Characteristics of participants by case and control status.**

Characteristic	Overall, N = 1,996	Cases, N = 434	Controls, N = 1,562	P-value	SMD

Age group* (years)					0.052
1-4	448 (22.4%)	94 (21.7%)	354 (22.7%)	Reference	
5-9	344 (17.2%)	81 (18.7%)	263 (16.8%)	0.5329	
10-19	467 (23.4%)	99 (22.8%)	368 (23.6%)	0.5238	
20-39	379 (19.0%)	82 (18.9%)	297 (19.0%)	0.4136	
40-59	240 (12.0%)	53 (12.2%)	187 (12.0%)	0.6040	
≥60	118 (5.9%)	25 (5.8%)	93 (6.0%)	0.4032	
Sex					0.014
Female	963 (48.2%)	207 (47.7%)	756 (48.4%)	Reference	
Male	1,033 (51.8%)	227 (52.3%)	806 (51.6%)	0.3057	
Vaccination status					0.274**
Not Vaccinated	1,118 (56.0%)	285 (65.7%)	833 (53.3%)	Reference	
One Dose	622 (31.2%)	96 (22.1%)	526 (33.7%)	<0.0001	
Two Doses	256 (12.8%)	53 (12.2%)	203 (13.0%)	0.0928	
Vaccination card unavailable	119 (13.6%)	18 (12.4%)	101 (13.8%)	0.4340	0.042

Data are n (%). * Age group refers to the age on the first day of the second mass vaccination campaign
round (1 October 2020). **Standard mean difference (SMD) between participants who reported receipt of
one dose of kOCV and those who were not vaccinated.

Additional data on socio-demographic and household characteristics were collected in SP2
(Table 2, Table S4). Cases were more likely to report drinking water from an unimproved source
compared to controls (odds ratio [OR] 1·82; 95% CI 1·15-2·86). Likewise, cases were more
likely to use toilets shared by multiple households than controls (OR 1·59; 95% CI 1·10-2·30).
Although likely an artifact of hygiene kit distribution that focused on case households, we found
that cases were more likely to live in households with soap and water available for handwashing
(OR 1·85; 95% CI 1·20–2·85).

Table 2. Characteristics of study participants in the vaccine effectiveness analysis 24-31
months after vaccination (Study Period 2)

Characteristic	Overall, N = 814	case, N = 167	control, N = 647	P-value	SMD
Age (years), median (IQR)	9.0 (4.0, 23.0)	8.0 (4.0, 22.5)	10.0 (4.0, 23.5)		0.032
Age group (years)*					0.160
1-4	235 (28.9%)	44 (26.3%)	191 (29.5%)	Ref.	
5-9	176 (21.6%)	44 (26.3%)	132 (20.4%)	0.05	
10-19	161 (19.8%)	30 (18.0%)	131 (20.2%)	0.85	
20-39	130 (16.0%)	26 (15.6%)	104 (16.1%)	0.98	
40-59	71 (8.7%)	16 (9.6%)	55 (8.5%)	0.78	
≥60	41 (5.0%)	7 (4.2%)	34 (5.3%)	0.77	
Sex					0.035
Female	406 (49.9%)	81 (48.5%)	325 (50.2%)	Ref.	
Male	408 (50.1%)	86 (51.5%)	322 (49.8%)	0.06	
Education attainment					0.150
None or primary	65 (27.2%)	13 (31.0%)	52 (26.4%)	Ref.	
Lower secondary	36 (15.1%)	6 (14.3%)	30 (15.2%)	0.75	
Upper secondary	120 (50.2%)	19 (45.2%)	101 (51.3%)	0.40	

Bachelor or higher	18 (7.5%)	4 (9.5%)	14 (7.1%)	0.56	
Occupation					0.126
No work	92 (11.3%)	23 (13.8%)	69 (10.7%)	Ref.	
Preschool children	176 (21.6%)	39 (23.4%)	137 (21.2%)	0.93	
Students	354 (43.5%)	70 (41.9%)	284 (43.9%)	0.57	
Informal work	154 (18.9%)	28 (16.8%)	126 (19.5%)	0.20	
Salaried	38 (4.7%)	7 (4.2%)	31 (4.8%)	0.40	
Household size, median (IQR)	7.0 (6.0, 9.0)	7.0 (5.0, 9.0)	7.0 (6.0, 9.0)	0.35	0.032
Children under five years old in the household					0.111
Zero	192 (23.6%)	42 (25.3%)	150 (23.2%)	Ref.	
1-2	536 (65.9%)	103 (62.0%)	433 (66.9%)	0.43	
≥3	85 (10.5%)	21 (12.7%)	64 (9.9%)	0.34	
Missing	1	1	0		
Living in household with improved drinking water source	538 (66.7%)	100 (60.2%)	438 (68.4%)	0.0098	0.172
Living in household with shared toilet					0.2130
Private	375 (46.1%)	63 (37.7%)	312 (48.2%)	Ref.	
Shared	439 (53.9%)	104 (62.3%)	335 (51.8%)	0.0140	
Living in household with improved toilet	495 (60.8%)	102 (61.1%)	393 (60.7%)	0.87	0.007
Soap and water available for handwashing	355 (43.6%)	85 (50.9%)	270 (41.7%)	0.0054	0.185
Electricity in household	312 (38.3%)	53 (31.7%)	259 (40.0%)	0.0279	0.174
Wealth index, median (IQR) ***	-2.2 (-45.6, 35.4)	-15.7 (-51.0, 30.8)	-2.2 (-45.6, 36.8)	0.0236	0.167
Vaccination status					0.222
Not Vaccinated	439 (53.9%)	100 (59.9%)	339 (52.4%)	Ref.	
One Dose	270 (33.2%)	42 (25.1%)	228 (35.2%)	0.0198	
Two Doses	105 (12.9%)	25 (15.0%)	80 (12.4%)	0.97	
Vaccination card available	56 (14.9%)	11 (16.4%)	45 (14.6%)	0.41	0.050

*Age group refers to the age on the first day of the second mass vaccination campaign round (01 October
2020). **The question about education attainment was only asked to individuals aged ≥ 18 years. ***
Wealth index was multiplied by 100. The higher the wealth index the richer the household. **** The
distribution of age and sex of the cases and controls does not match perfectly because the number of
controls included for each case varied slightly due to enrolled controls either not meeting the eligibility
criteria (e.g., not living in Uvira during vaccination) or not recalling their vaccination status.

Combining data from both study periods, 12-31 months post-vaccination, we estimated an

unadjusted and adjusted single-dose VE of 45·9% (95% Confidence Interval [CI] 29·5–58·5) and

44·4% (95% CI 27·3–57·4).

In SP1, 12–17 months after vaccination, we estimated an unadjusted and adjusted single-dose

VE of 51·7% (95% CI: 31·8–65·8) and 48·2% (95% CI: 26·4–63·5). In SP2, 24–31 months after

vaccination, we estimated an unadjusted VE of 35·2% (95% CI: 1·6–57·4) and an adjusted VE of

45·6% (95% CI: 14·1–65·5). The adjusted VE for 1–4-year-olds was 47·4% (95% CI: -25.0·2–
77·2) in SP1 and 31·9% (95% CI: -58·5–70.8) in SP2, suggesting the potential of a more rapid
decline in protection among this age group (Table 3).

Table 3. Effectiveness of a single dose of oral cholera vaccine, 12-17 months and 24-31
months after vaccination campaigns.

Population	Cases (effective n†)	Controls (effective n[†])	Unadjusted VE (95% CI)	Adjusted VE* (95% CI)
12-31 months after vaccination				
Overall	375 (300)	1359 (554)	45.9% (29.5–58.5)	44.4% (27.3–57.4)
1-4 years	74 (56)	264 (117)	46.4% (8.0–68.8)	39.4% (-6.6–65.5)
≥5 years	296 (228)	994 (415)	45.8% (27–59.7)	45.7% (26.6–59.9)
12-17 months after vaccination (Study Period 1)				
Overall	233 (184)	792 (332)	51.7% (31.8–65.8)	48.2% (26.4–63.5)
1-4 years	38 (27)	137 (55)	47.9% (-17.8–76.9)	47.4% (-25.0–77.9)
≥5 years	192 (150)	614 (267)	52.6% (30.9–67.4)	48.3% (24.2–64.8)
24-31 months after vaccination (Study Period 2)				
Overall	142 (116)	567 (222)	35.2% (1.6–57.4)	45.6% (14.1–65.5)
1-4 years	36 (29)	127 (62)	44.3% (-15.0–73.0)	31.9% (-58.5–70.8)
≥5 years	104 (78)	380 (148)	31.2% (-12–57.7)	50.3% (15.7–70.7)

*In SP1 and in analyses combining data from both study periods, we only adjusted for age as a
continuous variable. [†]Effective number of cases and controls is the sample size that effectively contributes
to estimates of effectiveness in the conditional logistic regression models. Those participants in matched
case-control sets where all people have the same vaccination status do not contribute to the estimates, nor
do those who either do not know their vaccination status or the number of doses they received.

In secondary analyses, we estimated the adjusted cumulative VE across both study periods for at
least one dose of kOCV to be 39·9% (95% CI: 24·2–52·4, Table S6). This estimate, which
includes those who report having received two doses of kOCV, is slightly lower than our single-
dose estimate and is driven by unexpectedly low, though uncertain, estimates for 1-4-year-olds in
SP1 (Table S3). We were unable to reliably estimate two-dose VE due to a limited effective
sample size, with post-hoc power calculations suggesting we had 16.4% power to detect
significant vaccine protection (Appendix).

Discussion

We found that a single dose of Euvichol-Plus kOCV provided protection against cholera for at
least the 31-month period post-vaccination. Our study provides unique, policy-relevant insights
into kOCV protection as we estimated single-dose effectiveness from the only available and
most widely used cholera vaccine today, including estimates of effectiveness for 1-4-year-olds
and at discrete time windows after vaccination. Our results suggest that at least in cholera
endemic areas like Uvira, the use of one kOCV dose may provide significant protection on the
scale of years rather than just months.

To date, one randomized trial[17,18] and seven observational studies have included estimates of
one-dose protection of kOCVs.[7–9,13–15,27] Most of these studies have been short-term estimates of
protection measured for just a few months after vaccination and showed similar levels of
protection to two doses on this timescale. Two notable exceptions where protection was
measured over a longer period include a randomized trial in Bangladesh and a case-control study
in Haiti, both using Shanchol®. The Bangladesh trial was conducted for two years and estimated
54% (95% CI: 16 to 75) efficacy in the first year and 67% (43 to 81) in the second year post-
vaccination among those five years and older.[17] Secondary analyses from a case-control study in
Haiti predicted that a single dose of kOCV (Shanchol®) would confer 58% (95% CI: 4 to 82%)
protection at 16 months post-vaccination, with the confidence intervals including zero protection
from 17-months post-vaccination and onward.[14] Our results are consistent with these previous
studies in showing significant protection for the overall population for longer than a year, though
it is important to note that Uvira, like Haiti (at the time of the study) and Bangladesh, is endemic
for cholera so the first dose may have acted as a booster for previously exposed individuals.
Furthermore, it is possible that previous exposures to enterotoxigenic *Escherichia coli*, which has
been identified among diarrhoea cases in Uvira and has a antigenically similar toxin to toxigenic
V. cholerae, could contribute to background immunity to severe disease in these settings.[29] More
work is needed to characterize the epidemiologic settings where one dose may provide
comparable levels of protection to the full regimen, and might include leveraging historic
incidence rates of cholera or, perhaps, population-level immunologic measures of previous
exposures.[30]

Before this study, only one estimate of single-dose protection of a kOCV in 1-4-year-olds had
been published. This trial, in Bangladesh, suggested that young children did not benefit from a
single dose of Shanchol, even during the first six months post-vaccination.[17,18] While our
estimates of Euvichol-Plus effectiveness in this age group come with large uncertainty, the
similar point estimates between 1-4 year olds and older individuals at 12-17 months post-
vaccination suggests that they may have similar protection over this time frame. This observation
is in line with studies showing similar levels of protection after natural infection between the two
age groups.[31] Conflicting estimates between young children and older individuals have also been
observed in kOCV studies with the full dose regimen, though there are only a handful of studies
that present age-stratified estimates. Although most studies have found lower effectiveness in
young children, the difference in protection has been highly variable with large uncertainty (e.g.,
ranging from no apparent difference in Vietnam after 10 months,[32] to 73% lower protective
efficacy among children in Bangladesh over 6 months post-vaccination[18]). If children in Uvira
were indeed protected by a single dose of Euvichol-Plus, the contrast with other studies could be
explained by several factors including pre-existing population immunity and season of
vaccination as shown with other diseases,[33] differences both in gut microbiota composition and
in prevalence of enteropathy.[34,35]

While the focus of the study was to understand the direct effectiveness of oral cholera vaccine,
our analysis of potential risk factors highlighted key differences between cases and matched
controls. Our results confirm the associations between cholera and markers of poverty, like using
a shared latrine, using an unimproved source for drinking water and not having electricity in the
household. While kOCV provides protection against cholera, tackling fundamental risk factors
like access to safe water and sanitation are needed to sustainably control the disease.

This study comes with several limitations. First, like many previous kOCV effectiveness studies,
the vaccination status was self-reported,[7,14,15] and only 18 cases were able to provide a
vaccination card. Measurements of the number of doses received months to years after a mass
vaccination campaign is prone to recall bias, particularly in a place like Uvira where mass
vaccination campaigns with different antigens are common. To minimize biases in classification
of vaccination status, we used visual aids and a series of structured questions, and hospital and
study staff reassured patients that their responses to the study questions would in no way affect
their care. Though enumerators were not blinded to the vaccination status of the cases while
enrolling their matched controls, the vaccine coverage among controls was like that measured in
community coverage surveys. Furthermore, sensitivity analyses restricted to only those with a
vaccination card revealed similar effectiveness estimates (Table S5). There were slight
differences in the protocols of the case-control study in each study period, challenging the
interpretability of the joint estimates from both periods. However, in sensitivity analyses
simulating similar diagnostic criteria for cases in SP1 as SP2, our qualitative findings remained
consistent (Table S6). The retrospective recruitment of controls for cases admitted during the
SP1 precluded adjustment for individual and household factors that may have influenced cholera
disease risk or vaccine acceptability and could also have led to differential recall of vaccination
status among cases and their controls. Even in SP2, our VE estimates could still be confounded
by unmeasured factors. Even though the number of cases under five years of age was higher than
in most published VE studies, our sample size in this important age group was still small and led
to wide confidence intervals around VE estimates (Table S6). Finally, we were unable to obtain
reliable estimates of two dose protection partly because few cases reported receipt of two doses
of kOCV due to low vaccination coverage in the population, and potentially because of
uncertainty in the reporting of more than one dose of kOCV (Tables S3 and S4).
424
Our findings, combined with data from dose-interval studies conducted in Cameroon and
Zambia[36,37], suggest that providing a second dose a year or more after the first could lead to
better and longer lasting protection against cholera than the current two-dose series, at least
among older children and adults. While more data are needed across different settings and for
longer periods of time, our study extends the current evidence base on protection from a single-
dose of kOCV, and more specifically on protection from Euvichol-Plus, the most widely used
cholera vaccine available today.
432

Declarations

Funding

This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062).

Authors' contributions

Conceptualization: EBM, ASA, JK. Data curation: EBM, JDH, HX, CH, PMB, ASA. Formal analysis: EBM, ASA. Data interpretation: EBM, ASA, JK, JL, EL. Funding acquisition: ASA, KG, OC. Investigation: EBM, PMB, CH, HX, JDH, BBR, MI, ETT, FK, TBM, AD, EL, DL, JK, ASA. Methodology: EBM, ASA, CH, JK. Project Administration: EBM, PMB, MD, DMB, HKM, CH, ASA, KG. Resources: PWO, JMS, DMB, AD, JK, OL. Software: EBM, JDH, HX, ASA. Supervision: ASA, JK. Validation: EBM, ASA. Visualization - EBM, ASA. Writing - original draft - EBM, ASA. Writing: review & editing: all authors.

Acknowledgements

We are thankful to Faraja Masema Lulela, Joël Faraja Zigashane Mashauri, Jean-Marie Masugamuhanya Cirhonda, the CTCs nurses and field investigators for their support for the data collection. We also thank the Head of the Uvira Health Zone, Dr Panzu Nimi, and the Director of the Uvira General Referral Hospital, Dr Salomon Mashupe, for their operational and administrative support throughout this study. We would also like to thank the MSF GIS Centre, including Frederic Ham and Edith Rogenhofer, for their assistance with acquiring satellite imagery data.

Data sharing

Code and data from this study are available at
https://github.com/HopkinsIDD/uvira_onedose_ocv_ve.

References

1   Deshpande A, Miller-Petrie MK, Lindstedt PA, *et al.* Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. *The Lancet Global Health* 2020; **8**: e1162–85.

2   World Health Organization. Global Task Force on Cholera Control. Ending Cholera, a Global Roadmap to 2030. World Health Organization, 2017.

3   Bi Q, Ferreras E, Pezzoli L, *et al.* Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 1080–8.

4   Ali M, Qadri F, Kim DR, *et al.* Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. *Lancet Infect Dis* 2021; **21**: 1407–14.

5   Burki T. Addressing the shortage of cholera vaccines. *Lancet Infect Dis* 2022; **22**: 1674–5.

6   Odevall L, Hong D, Digilio L, *et al.* The Euvichol story - Development and licensure of a safe,
effective and affordable oral cholera vaccine through global public private partnerships. *Vaccine*
2018; **36**: 6606–14.

7   Luquero FJ, Grout L, Ciglenecki I, *et al.* Use of Vibrio cholerae vaccine in an outbreak in Guinea. *N
Engl J Med* 2014; **370**: 2111–20.

8   Azman AS, Parker LA, Rumunu J, *et al.* Effectiveness of one dose of oral cholera vaccine in
response to an outbreak: a case-cohort study. *Lancet Glob Health* 2016; **4**: e856–63.

9   Grandesso F, Kasambara W, Page A-L, *et al.* Effectiveness of oral cholera vaccine in preventing
cholera among fishermen in Lake Chilwa, Malawi: A case-control study. *Vaccine* 2019; **37**: 3668–
76.

10 Sialubanje C, Kapina M, Chewe O, *et al.* Effectiveness of two doses of Euvichol-plus oral cholera
vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia.
BMJ Open 2022; **12**: e066945.

11 Bouhénia M. Overview of the OCV use in 2022. 2022; published online Oct 11.
https://www.gtfcc.org/events/9th-meeting-of-the-gtfcc-working-group-on-oral-cholera-vaccine/
(accessed May 10, 2023).

12 World Health Organization. Shortage of cholera vaccines leads to temporary suspension of two-dose
strategy, as cases rise worldwide. 2022; published online Oct 19. https://www.who.int/news/item/19-
10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy--as-
cases-rise-worldwide (accessed March 24, 2023).

13 Khatib AM, Ali M, von Seidlein L, *et al.* Effectiveness of an oral cholera vaccine in Zanzibar:
findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis* 2012;
12: 837–44.

14 Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one
and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control
study. *Lancet Glob Health* 2018; **6**: e1028–35.

15 Ferreras E, Blake A, Chewe O, *et al.* Alternative observational designs to estimate the effectiveness
of one dose of oral cholera vaccine in Lusaka, Zambia. *Epidemiol Infect* 2020; **148**: e78.

16 Ivers LC, Hilaire IJ, Teng JE, *et al.* Effectiveness of reactive oral cholera vaccination in rural Haiti: a
case-control study and bias-indicator analysis. *Lancet Glob Health* 2015; **3**: e162–8.

17 Qadri F, Ali M, Lynch J, *et al.* Efficacy of a single-dose regimen of inactivated whole-cell oral
cholera vaccine: results from 2 years of follow-up of a randomised trial. *Lancet Infect Dis* 2018; **18**:
666–74.

18 Qadri F, Wierzba TF, Ali M, *et al.* Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in
Bangladesh. *N Engl J Med* 2016; **374**: 1723–32.

19 Bugeme PM, Xu H, Hutchins C, *et al.* Cholera deaths during outbreaks in Uvira, Eastern Democratic
Republic of Congo, September 2021-January 2023. bioRxiv. 2023; published online June 3.
DOI:10.1101/2023.05.26.23290528.

20 Schyns C, Fossa A, Mutombo-Nfenda, *et al.* Cholera in Eastern Zaire, 1978. *Ann Soc Belg Med Trop*

1979; **59**: 391–400.

21   Jeandron A. Tap water access and its relationship with cholera and other diarrhoeal diseases in an
urban, cholera-endemic setting in the Democratic Republic of the Congo. 2020; published online
Dec 12. DOI:10.17037/PUBS.04659288.

22   Jeandron A, Cumming O, Kapepula L, Cousens S. Predicting quality and quantity of water used by
urban households based on tap water service. *npj Clean Water* 2019; **2**: 1–9.

23   Gaiffe M, Dross C, Malembaka EB, Ross I, Cumming O, Gallandat K. A fuzzy inference-based
index for piped water supply service quality in a complex, low-income urban setting. *Water Res*
2023; : 120316.

24   Gallandat K, Macdougall A, Jeandron A, *et al.* 1 Improved water supply infrastructure to reduce
acute diarrhoeal diseases and 2 cholera in Uvira, Democratic Republic of the Congo: results and
lessons learned 3 from a pragmatic trial. https://osf.io/na47d/download (accessed July 23, 2023).

25   Debes AK, Ateudjieu J, Guenou E, *et al.* Clinical and Environmental Surveillance for Vibrio
cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North
Region of Cameroon. *Am J Trop Med Hyg* 2016; **94**: 537–43.

26   Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biom J* 2008;
50: 346–63.

27   Wierzba TF, Kar SK, Mogasale VV, *et al.* Effectiveness of an oral cholera vaccine campaign to
prevent clinically-significant cholera in Odisha State, India. *Vaccine* 2015; **33**: 2463–9.

28   Haney DJ, Lock MD, Gurwith M, *et al.* Lipopolysaccharide-specific memory B cell responses to an
attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.
Vaccine 2018; **36**: 2768–73.

29   Clemens JD, Sack DA, Harris JR, *et al.* Cross-Protection by B Subunit-Whole Cell Cholera Vaccine
Against Diarrhea Associated with Heat-Labile Toxin-Producing Enterotoxigenic Escherichia coli:
Results of a Large-Scale Field Trial. *J Infect Dis* 1988; **158**: 372–7.

30   Azman AS, Lessler J, Luquero FJ, *et al.* Estimating cholera incidence with cross-sectional serology.
Sci Transl Med 2019; **11**. DOI:10.1126/scitranslmed.aau6242.

31   Ali M, Emch M, Park JK, Yunus M, Clemens J. Natural Cholera Infection–Derived Immunity in an
Endemic Setting. *J Infect Dis* 2011; **204**: 912–8.

32   Trach DD, Clemens JD, Ke NT, *et al.* Field trial of a locally produced, killed, oral cholera vaccine in
Vietnam. *Lancet* 1997; **349**: 231–5.

33   Moore SE, Collinson AC, Fulford AJC, *et al.* Effect of month of vaccine administration on antibody
responses in The Gambia and Pakistan. *Trop Med Int Health* 2006; **11**: 1529–41.

34   Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clin
Microbiol Rev* 2019; **32**. DOI:10.1128/CMR.00084-18.

35   Porras AM, Shi Q, Zhou H, *et al.* Geographic differences in gut microbiota composition impact
susceptibility to enteric infection. *Cell Rep* 2021; **36**: 109457.

36   Mwaba J, Chisenga CC, Xiao S, *et al.* Serum vibriocidal responses when second doses of oral
cholera vaccine are delayed 6 months in Zambia. *Vaccine* 2021; **39**: 4516–23.

37   Ateudjieu J, Sack DA, Nafack SS, *et al.* An Age-stratified, Randomized Immunogenicity Trial of
Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. *Am J Trop Med Hyg* 2022;
107: 974–83.